| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:52:00 UTC |
|---|
| HMDB ID | HMDB0015511 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Bromazepam |
|---|
| Description | Bromazepam is only found in individuals that have used or taken this drug. It is one of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances.Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced. |
|---|
| Structure | BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1 InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19) |
|---|
| Synonyms | | Value | Source |
|---|
| Lectopam | Kegg | | 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one | HMDB | | 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one | HMDB | | 1a Brand OF bromazepam | HMDB | | Bromazepam lichtenstein brand | HMDB | | Bromazepam beta | HMDB | | Heumann brand OF bromazepam | HMDB | | Lexatin | HMDB | | Betapharm brand OF bromazepam | HMDB | | Apo-bromazepam | HMDB | | Apotex brand OF bromazepam | HMDB | | Bromaz 1a pharma | HMDB | | Hexal brand OF bromazepam | HMDB | | CT-Arzneimittel brand OF bromazepam | HMDB | | Durazanil | HMDB | | Aliud brand OF bromazepam | HMDB | | Apo bromazepam | HMDB | | Bromazepam heumann | HMDB | | Bromazepam ratiopharm | HMDB | | Bromazepam-neuraxpharm | HMDB | | Bromazepam-ratiopharm | HMDB | | Gen-bromazepam | HMDB | | Lexomil | HMDB | | Lexotan | HMDB | | Roche brand OF bromazepam | HMDB | | Neuraxpharm brand OF bromazepam | HMDB | | Ratiopharm brand OF bromazepam | HMDB | | Anxyrex | HMDB | | BromaLich | HMDB | | Bromazanil | HMDB | | Bromazepam al | HMDB | | Bromazepam roche brand | HMDB | | Gen bromazepam | HMDB | | Genpharm brand OF bromazepam | HMDB | | Irex brand OF bromazepam | HMDB | | Lexotanil | HMDB | | Lichtenstein brand OF bromazepam | HMDB | | Merck dura brand OF bromazepam | HMDB | | Bromazep von CT | HMDB | | CT Arzneimittel brand OF bromazepam | HMDB | | Beta, Bromazepam | HMDB | | Bromazepam neuraxpharm | HMDB | | Von CT, bromazep | HMDB |
|
|---|
| Chemical Formula | C14H10BrN3O |
|---|
| Average Molecular Weight | 316.153 |
|---|
| Monoisotopic Molecular Weight | 315.000724604 |
|---|
| IUPAC Name | 7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one |
|---|
| Traditional Name | bromazepam |
|---|
| CAS Registry Number | 1812-30-2 |
|---|
| SMILES | BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1 |
|---|
| InChI Identifier | InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19) |
|---|
| InChI Key | VMIYHDSEFNYJSL-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzodiazepines |
|---|
| Sub Class | 1,4-benzodiazepines |
|---|
| Direct Parent | 1,4-benzodiazepines |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,4-benzodiazepine
- Alpha-amino acid or derivatives
- Aryl bromide
- Aryl halide
- Pyridine
- Benzenoid
- Heteroaromatic compound
- Carboxamide group
- Ketimine
- Lactam
- Secondary carboxylic acid amide
- Carboxylic acid derivative
- Azacycle
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organobromide
- Organohalogen compound
- Hydrocarbon derivative
- Imine
- Organic nitrogen compound
- Organic oxide
- Carbonyl group
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.04 g/L | Not Available | | LogP | 2.05 | SANGSTER (1994) |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 159.8 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.77 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.3075 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.28 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 30.4 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1856.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 317.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 139.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 195.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 153.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 386.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 529.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 64.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 939.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 268.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1151.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 323.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 274.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 293.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 62.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 37.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Bromazepam,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=N2)C2=CC(Br)=CC=C21 | 2375.1 | Semi standard non polar | 33892256 | | Bromazepam,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=N2)C2=CC(Br)=CC=C21 | 2481.4 | Standard non polar | 33892256 | | Bromazepam,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=N2)C2=CC(Br)=CC=C21 | 3788.8 | Standard polar | 33892256 | | Bromazepam,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=N2)C2=CC(Br)=CC=C21 | 2603.8 | Semi standard non polar | 33892256 | | Bromazepam,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=N2)C2=CC(Br)=CC=C21 | 2700.3 | Standard non polar | 33892256 | | Bromazepam,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=N2)C2=CC(Br)=CC=C21 | 3875.7 | Standard polar | 33892256 |
|
|---|
| General References | - Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
- Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI: Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70. [PubMed:2882883 ]
- van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. [PubMed:8846617 ]
- Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. [PubMed:14517708 ]
|
|---|